Delix Therapeutics

Delix Therapeutics is an American biotechnology company headquartered in Boston, Massachusetts, focused on developing medicines that promote neuroplasticity for central nervous system disorders. Its work is directed primarily toward conditions including depression, post-traumatic stress disorder, and substance use disorders. The company was founded in 2019 by David E. Olson and Nick Haft after Olson's research indicated that psychedelic compounds can produce strong neuroplasticity-promoting effects. Delix was established around the idea that these effects might be separated from the perceptual and behavioral changes associated with hallucinogenic psychedelics. The company describes its approach in terms of psychoplastogens, also called neuroplastogens: small molecules intended to stimulate structural and functional changes in neural circuits. Rather than developing only classic hallucinogenic compounds such as psilocybin, Delix has pursued non-hallucinogenic analogs that could potentially be administered more broadly and without requiring the intensive clinical supervision associated with psychedelic experiences. Its research has included analogs of known psychedelic molecules, including compounds related to ibogaine and 5-MeO-DMT. According to the cited company history, Delix has synthesized more than 2,000 novel psychoplastogens. Delix's development strategy has emphasized compounds intended to retain neuroplasticity-related activity while avoiding hallucinations, cardiotoxicity, and psychostimulant properties associated with some earlier neuroplasticity-promoting drug candidates. The company's disclosed candidates include zalsupindole, also known as DLX-001 and AAZ-A-154; tabernanthalog, or DLX-007; JRT; and DLX-159. The company has licensed several of these compounds from the University of California, Davis. In 2021, Delix raised a Series A financing round described in the reference material as the largest in its sector at that time. During the same year, it joined the National Institute on Drug Abuse's industry partnering program to evaluate psychoplastogens in models of substance use disorder. Delix also expanded its senior leadership during 2021, adding a chief executive officer, chief scientific officer, and chief medical officer, although the available reference material does not identify those executives by name. The company received industry recognition during its early development. It was included in Fierce Biotech's 2021 Fierce 15 selection, was named Nature's Spinout of the Year in 2022, and received the Healthcare Businesswomen's Association ACE award in 2022. In 2023, it was reported as a finalist for the Prix Galien award for Best Startup and for the BWB Biotech Innovation of the Year award, while winning a Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year. Delix is a private drug-development company rather than a consumer-facing pharmaceutical brand. Its business scope centers on discovery research, preclinical development, licensing, and potential clinical translation of small-molecule neuroplastogens. The available material does not establish that any Delix candidate has received regulatory approval or reached commercial sales.

Delix Therapeutics was established in 2019 by David E. Olson and Nick Haft. Its origin was closely connected to Olson's research into psychedelics and neuroplasticity. That research supported the proposition that psychedelic compounds can be highly potent promoters of changes in neuronal structure and function. Delix was formed to translate this scientific insight into medicines that could potentially treat psychiatric and neurological conditions without producing the hallucinogenic experience associated with many classic psychedelics. The company's central research concept is the psychoplastogen, or neuroplastogen. These compounds are intended to promote adaptive changes in neural circuits and may be relevant to disorders in which stress, trauma, addiction, or mood disturbances are associated with impaired neural plasticity. Delix has concentrated on non-hallucinogenic molecules, viewing them as potentially more scalable than treatments requiring a supervised psychedelic session. The company has also sought to engineer candidates without cardiotoxicity and psychostimulant characteristics associated with some earlier compounds in the broader neuroplasticity field. Delix's discovery work has produced a large library of novel compounds. The reference material states that the company had synthesized more than 2,000 psychoplastogens, including analogs of molecules such as ibogaine and 5-MeO-DMT. Named candidates include zalsupindole, or DLX-001 and AAZ-A-154; tabernanthalog, or DLX-007; JRT; and DLX-159. Several compounds were licensed from the University of California, Davis, linking the company's pipeline to academic discoveries and translational drug-development work. The available material also identifies DLX-2270, DLX-0002700, and (R)-MDDMA in connection with the broader set of compounds associated with Delix, but it does not provide sufficient detail to characterize their development status or therapeutic indications. A major corporate milestone came in September 2021, when Delix completed a Series A financing round. The round was described as the largest in the space at that time, although the amount and investor list are not included in the supplied reference. In the fall of 2021, the company also entered the National Institute on Drug Abuse industry partnering program. That collaboration was intended to support screening of psychoplastogens in models of substance use disorder, broadening the company's research beyond depression and post-traumatic stress disorder. Delix expanded its leadership team in 2021 with the addition of a chief executive officer, chief scientific officer, and chief medical officer. The supplied material does not name these executives, so they are not listed individually in this dossier. The expansion reflected the company's movement from an early discovery organization toward a more operational drug-development structure. The company received several forms of external recognition as the field developed. In 2021 it was selected for Fierce Biotech's Fierce 15. In 2022, Nature named Delix Spinout of the Year, and the company received the Healthcare Businesswomen's Association ACE award. In 2023, Delix was a finalist for the Prix Galien Best Startup award and the BWB Biotech Innovation of the Year award, while winning a Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year. Delix remains a private biotechnology company whose principal activity is the discovery and development of investigational central nervous system medicines. The available reference does not document an approved product, commercial launch, public listing, or completed regulatory authorization. Its present identity is therefore best understood as that of a research-driven pharmaceutical developer focused on non-hallucinogenic neuroplasticity therapeutics.

• 2023

  Received neuroscience therapeutics award

  [1]Delix Therapeuticsen.wikipedia.org

  Delix won a Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year and was also reported as a finalist for two other startup and biotech innovation awards.

• 2022

  Received spinout and healthcare innovation recognition

  [1]Delix Therapeuticsen.wikipedia.org

  Nature named Delix Spinout of the Year, and the company received the Healthcare Businesswomen's Association ACE award.

• 2021

  Series A financing completed

  [1]Delix Therapeuticsen.wikipedia.org

  Delix secured a Series A financing round described as the largest in the sector at that time; the financing amount is not specified in the available material.

• 2021

  Joined NIDA industry partnering program

  [1]Delix Therapeuticsen.wikipedia.org

  Delix entered a National Institute on Drug Abuse industry partnering program to screen psychoplastogens in substance-use-disorder models.

• 2021

  Named to Fierce 15 of Biotech

  [1]Delix Therapeuticsen.wikipedia.org

  Delix was selected for Fierce Biotech's Fierce 15 recognition.

• 2019

  Company founded

  [1]Delix Therapeuticsen.wikipedia.org

  David E. Olson and Nick Haft founded Delix Therapeutics to develop non-hallucinogenic psychoplastogens and other neuroplasticity-promoting treatments.

Delix positions itself as a neuroscience biotechnology company seeking scalable, non-hallucinogenic alternatives to first-generation psychedelic and other neuroplasticity-promoting treatments. Its differentiation is based on designing small molecules that may preserve therapeutic neuroplasticity while reducing hallucinations and other safety or administration burdens.

• Investigational neuroplastogen

  Zalsupindole

  Zalsupindole, also identified as DLX-001 and AAZ-A-154, is a Delix drug candidate in the company's neuroplasticity-focused pipeline. It is intended to represent the company's approach of developing small molecules that can promote neuroplasticity without the hallucinogenic effects associated with some classic psychedelics. The supplied material does not establish its current clinical phase, approved indication, or commercial status.

• Investigational psychoplastogen

  Tabernanthalog

  Tabernanthalog, also known as DLX-007, is an investigational compound associated with Delix's non-hallucinogenic psychoplastogen program. It is an analog related to the company's broader effort to identify molecules capable of producing neuroplasticity-promoting effects while reducing the perceptual and safety liabilities of first-generation psychedelic treatments. The available material does not specify its development stage or regulatory status.

• Investigational neuroplastogen

  JRT

  JRT is one of the named small-molecule candidates in Delix Therapeutics' psychoplastogen portfolio. It is part of the company's discovery and development effort in central nervous system therapeutics, but the supplied reference does not provide a confirmed target, indication, clinical phase, or commercialization plan.

• Investigational neuroplastogen

  DLX-159

  DLX-159 is a disclosed Delix development candidate within the company's portfolio of neuroplasticity-promoting compounds. Delix's overall platform seeks non-hallucinogenic alternatives for CNS disorders such as depression and post-traumatic stress disorder. The available reference does not provide enough information to state a specific indication, trial phase, or regulatory milestone for DLX-159.

• 2021

  Entered NIDA industry partnering programStrategy

  Background

  Delix sought to extend evaluation of its psychoplastogen platform into substance use disorder research.

  Action taken

  The company joined the National Institute on Drug Abuse industry partnering program to screen compounds in models of substance use disorder.

  Aftermath

  The partnership broadened the publicly described research scope of Delix's platform, although the supplied material does not report specific clinical or regulatory outcomes.

  Source

• 2021

  Completed Series A financingOther

  Background

  Delix required additional capital to advance its neuroplastogen discovery and therapeutic-development programs.

  Action taken

  The company raised a Series A financing round in September 2021.

  Aftermath

  The financing supported continued work on neuroplastogens and neuroplasticity therapeutics. No financing amount or investor details are provided in the available material.

  Source

1. 1Delix Therapeuticsen.wikipedia.org